EVE Health Group has transitioned from development to early commercialisation, launching two pharmaceutical products under Australia's Special Access Scheme and expanding its reformulation pipeline targeting $30 billion markets.
- Commercial launch of Libbo® and Dyspro® under Special Access Scheme
- Pilot bioequivalence study initiated for Libbo®
- Expanded reformulation pipeline targeting sexual health and anticoagulants
- Raised $2.4 million through placements including cornerstone investor
- Appointed Ben Rohr as CEO to drive commercial execution
Transition from Development to Early Commercialisation
EVE Health Group (ASX:EVE) marked a pivotal year in FY2026 by moving its pharmaceutical portfolio from development into early commercial application. The company launched Libbo®, an oral dissolving film for erectile dysfunction (ED), and Dyspro®, a treatment targeting dysmenorrhoea and endometriosis, both made available to patients in Australia via the Therapeutic Goods Administration's Special Access Scheme Category B pathway. These launches were supported by dedicated digital health platforms and a national telehealth patient support program, underscoring EVE’s focus on integrating technology with pharmaceutical delivery.
Libbo® Commercial Launch and Clinical Progress
Libbo® delivers vardenafil through a fast-acting film designed for sublingual absorption, aiming to improve onset and consistency over conventional tablets. Early observational data suggests an onset of approximately 15 minutes; significantly faster than the typical hour for standard oral tablets. During the year, EVE completed manufacture and national distribution of Libbo®, supported by the men’s health education platform libx.com.au, which facilitates telehealth prescribing and pharmacy fulfilment.
Critically, EVE initiated a pilot bioequivalence clinical study for Libbo®, comparing it to an approved reference product in healthy males. This pilot study is a key step toward full regulatory registration, which is essential for expanding beyond Australia into international markets requiring formal product approval. EVE is actively engaging potential distribution partners across Asia, the Middle East, Europe, and North America to leverage established commercial channels post-registration.
Dyspro® Regulatory Clearance and Market Entry
Dyspro®, targeting the under-addressed condition of dysmenorrhoea affecting a majority of women of reproductive age, also achieved regulatory clearance under the TGA’s Special Access Scheme and Authorised Prescriber pathways. The product completed GMP manufacture and began dispatch to distribution partners, with initial patient prescriptions following promptly. To support uptake, EVE launched Reclaim My Cycle, an online education and community platform for patients and prescribers, alongside in-clinic education initiatives to boost prescriber confidence.
Pipeline Expansion into Sexual Health and Cardiovascular Markets
Building on the commercial foundation of Libbo® and Dyspro®, EVE significantly expanded its reformulation pipeline during the year. New candidates include a vardenafil erectile dysfunction spray, a dapoxetine premature ejaculation spray, a dual-molecule vardenafil-plus-dapoxetine formulation, and a reformulated apixaban program aimed at enhancing solubility and delivery of this widely prescribed anticoagulant. The combined target markets exceed US$30 billion globally, with apixaban alone part of a market forecast to reach US$87 billion by 2035.
Notably, EVE reported a breakthrough in apixaban solubility, achieving over 50 mg/mL using its proprietary technology; an 80-fold improvement over baseline. The company has lodged a provisional patent application for this technology, reflecting its commitment to innovation within established pharmaceutical compounds nearing patent expiry.
Capital Raising and Leadership Alignment
To fund its commercial rollout and pipeline expansion, EVE completed two placements raising a total of approximately $2.4 million, including a $400,000 commitment from a new cornerstone investor with pharmaceutical development expertise. Reflecting the company’s shift toward commercial execution, Ben Rohr was appointed CEO in April 2026, having played a central role in operational and commercial progress, including the Nextract acquisition and product launches. Damian Wood, the previous CEO, departed during the year.
Financial Results and Outlook
For FY2026, EVE reported a net loss of $1.89 million, slightly wider than the prior year’s $1.58 million loss, reflecting increased investment in commercial activities and clinical development. Revenues of $1.15 million were generated, primarily from the Meluka Australia consumer health business and early pharmaceutical sales. Cash reserves stood at $1.24 million at year-end, supported by recent capital raises.
Looking ahead, EVE has set clear milestones: completion of Libbo®’s pilot and pivotal bioequivalence studies leading to regulatory submissions; advancement of its expanded pipeline including sexual health and anticoagulant candidates; and establishment of licensing partnerships to leverage established manufacturing and distribution networks internationally. The company’s capital-light, partner-led model aims to scale its proprietary reformulation platform into a repeatable commercial engine.
Bottom Line?
EVE’s FY2026 marks a foundational shift from development to commercialisation, but the path to sustainable growth hinges on clinical study outcomes, regulatory approvals, and securing global partnerships.
Questions in the middle?
- Will EVE’s pilot bioequivalence study for Libbo® deliver data robust enough to accelerate regulatory approval and international market entry?
- How effectively can EVE convert its expanded reformulation pipeline into licensing deals without building capital-intensive infrastructure?
- What impact will the appointment of Ben Rohr as CEO have on accelerating commercial traction and managing cash burn?